FDA Approves ASCENIV™ (formerly referred to as RI-002), A Novel Intravenous Immune Globulin
See the Press Release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares:READ MOREADMA Biologics Announces Pricing of Public Offering of Common Stock
ADMA Biologics Announces Pricing of Public Offering of Common Stock:READ MOREADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock:READ MORE